COVID-19 Genetic Engineering Articles from medRxiv
- Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
- SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice
- First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical engineering
Biomedical Sciences
Related
COVID-19 Genetic Engineering Articles from Nature Biotechnology
COVID-19 Genetic Engineering Articles from The New England Journal of Medicine
COVID-19 Genetic Engineering Articles from The Lancet
COVID-19 Genetic Engineering Articles from Virologica Sinica
COVID-19 Genetic Engineering Articles from medRxiv
COVID-19 Genetic Engineering Articles from Asian Pacific Journal of Allergy and Immunology
COVID-19 Genetic Engineering Articles from Nature
COVID-19 Genetic Engineering Articles from Nature Nanotechnology
COVID-19 Science Translational Medicine Articles
COVID-19 Genetic Engineering from Nature
COVID-19 Genetic Engineering articles from Frontiers in Immunology
COVID-19 Genetic Engineering articles from European Journal of Pharmacology
Learn After
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice